[
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
    "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
    "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997700,
      "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
      "id": 136159393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1408826216/image_1408826216.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
      "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors",
    "summary": "PASADENA, Calif., July 31, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where",
    "url": "https://finnhub.io/api/news?id=60daefef7b857c59b6b50045a8adadf968751bf172cce80fe8e5c99c97541116",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992060,
      "headline": "Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors",
      "id": 136161063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "PASADENA, Calif., July 31, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where",
      "url": "https://finnhub.io/api/news?id=60daefef7b857c59b6b50045a8adadf968751bf172cce80fe8e5c99c97541116"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS",
    "summary": "Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
    "url": "https://finnhub.io/api/news?id=5e23428fe32c3f247c492f09534b400d36d29b109ae4b6c7ce78ec718b14e032",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992060,
      "headline": "AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS",
      "id": 136161062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.",
      "url": "https://finnhub.io/api/news?id=5e23428fe32c3f247c492f09534b400d36d29b109ae4b6c7ce78ec718b14e032"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
    "summary": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
    "url": "https://finnhub.io/api/news?id=c2d7a9ce3b26e01311ba0f78076a85091b7a82af8a7d2918853887f38d08db8e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753977060,
      "headline": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
      "id": 136168496,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 350-point fall led by losses in shares of UnitedHealth, Merck",
      "url": "https://finnhub.io/api/news?id=c2d7a9ce3b26e01311ba0f78076a85091b7a82af8a7d2918853887f38d08db8e"
    }
  },
  {
    "ts": null,
    "headline": "Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=84dcccc6a4cd08bc0b0505b03ae5044dd47118d5c01d46dba5452b2781b2e2ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753969502,
      "headline": "Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio",
      "id": 136155213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=84dcccc6a4cd08bc0b0505b03ae5044dd47118d5c01d46dba5452b2781b2e2ce"
    }
  },
  {
    "ts": null,
    "headline": "Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=3c37adbaac757e97a3f229ab151ca1c5a35dc17d2d58043a31b9f5a844cfe4d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753967704,
      "headline": "Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics",
      "id": 136155214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=3c37adbaac757e97a3f229ab151ca1c5a35dc17d2d58043a31b9f5a844cfe4d9"
    }
  },
  {
    "ts": null,
    "headline": "With 81% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns",
    "summary": "Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...",
    "url": "https://finnhub.io/api/news?id=2b32285c3ba1fccfadd1dc4ebd3a77310af5eeb0a019e9e573f36cb92c684665",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966827,
      "headline": "With 81% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns",
      "id": 136151894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...",
      "url": "https://finnhub.io/api/news?id=2b32285c3ba1fccfadd1dc4ebd3a77310af5eeb0a019e9e573f36cb92c684665"
    }
  },
  {
    "ts": null,
    "headline": "Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial",
    "summary": "Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a proof-of-concept study of SGX945 (dusquetide) in Behçet’s disease, a rare and chronic inflammatory condition. The session volume reached 28.71 million shares, significantly above the stock’s average daily volume of approximately 905,000, according to Benzinga Pro. The company reported that SGX945 achieved the trial’s primary goal of demonstrating biological efficacy in treating oral",
    "url": "https://finnhub.io/api/news?id=5ea268f27b63055f3455cefb296e4e932b995b92d434fcdb45eabeb0afe2ad2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966810,
      "headline": "Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial",
      "id": 136151895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a proof-of-concept study of SGX945 (dusquetide) in Behçet’s disease, a rare and chronic inflammatory condition. The session volume reached 28.71 million shares, significantly above the stock’s average daily volume of approximately 905,000, according to Benzinga Pro. The company reported that SGX945 achieved the trial’s primary goal of demonstrating biological efficacy in treating oral",
      "url": "https://finnhub.io/api/news?id=5ea268f27b63055f3455cefb296e4e932b995b92d434fcdb45eabeb0afe2ad2d"
    }
  },
  {
    "ts": null,
    "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
    "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
    "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753955100,
      "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
      "id": 136151802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
      "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21"
    }
  },
  {
    "ts": null,
    "headline": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
    "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
    "url": "https://finnhub.io/api/news?id=0993e4dc449036d1d6b6c28ed1f6c34e436cbf92c1cd937d4ca518ab043c7c25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954680,
      "headline": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
      "id": 136151803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
      "url": "https://finnhub.io/api/news?id=0993e4dc449036d1d6b6c28ed1f6c34e436cbf92c1cd937d4ca518ab043c7c25"
    }
  },
  {
    "ts": null,
    "headline": "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics",
    "summary": "The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Ir",
    "url": "https://finnhub.io/api/news?id=39f4af6403ea85af6b158ce0e988ed79f5a11e547aad05825448704ed30662f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753949520,
      "headline": "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics",
      "id": 136148872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Ir",
      "url": "https://finnhub.io/api/news?id=39f4af6403ea85af6b158ce0e988ed79f5a11e547aad05825448704ed30662f7"
    }
  },
  {
    "ts": null,
    "headline": "UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS analyst Trung Huynh raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $326 from $315 while keeping a Neutral rating on the shares. The firm told investors in a research note that it […]",
    "url": "https://finnhub.io/api/news?id=4b0d42b95f679af4fb1ef4313bd04fb7dd3c73b66486522bc7a3a41ae5dd04e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753934347,
      "headline": "UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating",
      "id": 136149056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS analyst Trung Huynh raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $326 from $315 while keeping a Neutral rating on the shares. The firm told investors in a research note that it […]",
      "url": "https://finnhub.io/api/news?id=4b0d42b95f679af4fb1ef4313bd04fb7dd3c73b66486522bc7a3a41ae5dd04e6"
    }
  }
]